Animal models of anxiety: An ethological perspective

Brazilian Journal of Medical and Biological Research

Volumn 30, Issue 3, 1997, Pages 289-304

  Rodgers, R J ^a   Cao, B J ^a   Dalvi, A ^a   Holmes, A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Animal models of anxiety; Behavioural profiling; Defence; Ethology; Pharmacology; Plus maze; Risk assessment

Indexed keywords

ANIMALIA; MAMMALIA;

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; SEROTONIN AGONIST; STEROID;

ANIMAL; ANIMAL BEHAVIOR; ANXIETY; DISEASE MODEL; LOCOMOTION; MAZE TEST; MENTAL STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BENZODIAZEPINES; DISEASE MODELS, ANIMAL; GABA AGONISTS; LOCOMOTION; MAZE LEARNING; SEROTONIN AGONISTS; STEROIDS; STRESS, PSYCHOLOGICAL;

EID: 0031091332     PISSN: 0100879X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0100-879X1997000300002     Document Type: Review

References (120)

1. File SE (1992). Behavioural detection of anxiolytic action. In: Elliott JM, Heal DJ & Marsden CA (Editors), Experimental Approaches to Anxiety and Depression. Wiley, Chichester, 25-44.
2. Green S & Hodges H (1991). Animal models of anxiety. In: Willner P (Editor), Behavioural Models in Psychopharmacology. CUP, Cambridge, 21-49.
3. Handley SL (1991). Serotonin in animal models of anxiety: the importance of stimulus and response. In: Idzikowski C & Cowen P (Editors), Serotonin, Sleep and Mental Disorder. Wrightson Biomedical, Petersfield, 89-115.
4. Lister RG (1990). Ethologically-based animal models of anxiety disorders. Pharmacology and Therapeutics, 46: 321-340.
5. Rodgers RJ & Cole JC (1994). The elevated plus-maze: pharmacology, methodology and ethology. In: Cooper SJ & Hendrie CA (Editors), Ethology and Psychopharmacology. Wiley, Chichester, 9-44.
6. Stephens DN & Andrews JS (1991). Screening for anxiolytic drugs. In: Willner P (Editor), Behavioural Models in Psychopharmacology. CUP, Cambridge, 50-75.
7. Treit D (1994). Animal models of anxiety and anxiolytic drug action. In: den Boer JA & Sitsen JMA (Editors), Handbook of Depression and Anxiety. Marcel Dekker, New York, 201-224.
8. Griebel G (1995). 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacology and Therapeutics, 65: 319-395.
9. 3 Antagonists and Benzodiazepines: Their Behavioural Pharmacology. Wiley, Chichester, 343-363.
10. Ashton H (1994). Guidelines for the rational use of benzodiazepines. Drugs, 48: 25-40.
11. American Psychiatric Association (1994). DSM-IV. APA, Washington DC.
12. Barrett JE (1991). Animal behaviour models in the analysis and understanding of anxiolytic drugs acting at serotonin receptors. In: Olivier B, Mos J & Slangen JL (Editors), Animal Models in Psychopharmacology. Birkhäuser, Basel, 37-57.
13. Beck AT & Emery G (1985). Anxiety Disorders and Phobias: A Cognitive Perspective. Basic Books, New York.
14. Marks IM (1987). Fears, Phobias, and Rituals: Panic, Anxiety and their Disorders. OUP, New York.
15. Eysenck MW (1991). Cognitive factors in clinical anxiety: potential relevance to therapy. In: Briley M & File SE (Editors), New Concepts in Anxiety. Macmillan Press, London, 418-433.
16. Willner P (1991). Behavioural models in psychopharmacology. In: Willner P (Editor), Behavioural Models in Psychopharmacology. CUP, Cambridge, 3-18.
17. Darwin CR (1872). The Expression of the Emotions in Man and Animals. John Murray, London.
18. Blanchard DC, Blanchard RJ & Rodgers RJ (1991). Risk assessment and animal models of anxiety. In: Olivier B, Mos J & Slangen JL (Editors), Animal Models in Psychopharmacology. Birkhäuser, Basel, 117-134.
19. Deakin JFW & Graeff FG (1991). 5-HT and mechanisms of defence. Journal of Psychopharmacology, 5: 305-315.
20. Beck AT (1976). Cognitive Therapy of the Emotional Disorders. New American Library, New York.
21. Clark DM (1989). Anxiety states: panic and generalized anxiety. In: Hawton K, Salkovkis PM, Kirk J & Clark DM (Editors), Cognitive Behaviour Therapy for Psychiatric Problems: a Practical Guide. Oxford Medical Publications, Oxford, 52-96.
22. Kidman A (1989). Neurochemical and cognitive aspects of anxiety disorders. Progress in Neurobiology, 32: 391-402.
23. Depaulis A & Bandler RJ (1991). The Midbrain Periaqueductal Gray Matter: Functional, Anatomical and Neurochemical Organization. Plenum Press, New York.
24. Davis M (1992). The role of the amygdala in fear and anxiety. Annual Review of Psychology, 15: 353-375.
25. LeDoux JE (1995). Emotion: clues from the brain. Annual Review of Psychology, 46: 209-235.
26. Edmunds M (1974). Defence in Animals. Longman, Harlow.
27. Ratner SC (1967). Comparative aspects of hypnosis. In: Gordon JE (Editor), Handbook of Clinical and Experimental Hypnosis. Macmillan, New York, 550-587.
28. Blanchard RJ, Blanchard DC, Rodgers RJ & Weiss SM (1990). The characterization and modelling of antipredator defensive behavior. Neuroscience and Biobehavioral Reviews, 14: 491-496.
29. Blanchard DC, Blanchard RJ, Rodgers RJ & Weiss SM (1990). Pharmacological and neural control of anti-predator defense in the rat. Aggressive Behavior, 16: 165-176.
30. Pinel JPJ & Treit D (1983). The conditioned defensive burying paradigm and behavioral neuroscience. In: Robinson T (Editor), Behavioral Approaches to Brain Research. OUP, Oxford, 212-234.
31. DeVry J, Benz U, Schreiber R & Traber J (1993). Shock-induced ultrasonic vocalization in young adult rats: a novel model for testing putative anti-anxiety drugs. European Journal of Pharmacology, 249: 331-339.
32. Winslow JT & Insel TR (1991). The infant rat separation paradigm: a novel test for novel anxiolytics. Trends in Pharmacological Sciences, 12: 402-404.
33. Blanchard RJ, Blanchard DC, Agullana R & Weiss SM (1991) Twenty-two kHz alarm cries to presentation of a predator, by laboratory rats living in visible burrow systems. Physiology and Behavior, 50: 967-972.
34. Blanchard RJ & Blanchard DC (1989). Anti-predator defensive behaviors in a visible burrow system. Journal of Comparative Psychology, 103: 70-82.
35. Blanchard RJ, Parmigiani S, Bjornson C, Masuda C, Weiss SM & Blanchard DC (1995). Antipredator behavior of Swiss-Webster mice in a visible burrow system. Aggressive Behavior, 21: 123-136.
36. Pinel JPJ & Mana MJ (1989). Adaptive interactions of rats with dangerous inanimate objects: support for a cognitive theory of defensive behavior. In: Blanchard RJ, Brain PF, Parmigiani S & Blanchard DC (Editors), Ethoexperimental Approaches to the Study of Behavior. Kluwer, Dordrecht, 137-155.
37. Molewijk HE, Van der Poel AM & Olivier B (1995). The ambivalent behaviour 'stretched attend posture' as a paradigm to characterize anxiolytic drugs. Psychopharmacology, 121: 81-90.
38. Kaesermann H-P (1986). Stretched attend posture, a non-social form of ambivalence, is sensitive to a conflict-reducing drug action. Psychopharmacology, 89: 31-37.
39. Garbe CM & Kemble ED (1994). Effects of prior agonistic experience on risk assessment and approach behavior evoked by familiar and unfamiliar conspecific odors. Aggressive Behavior, 20: 143-149.
40. Blanchard RJ, Yudko EB, Rodgers RJ & Blanchard DC (1993). Defense system psychopharmacology: an ethological approach to the pharmacology of fear and anxiety. Behavioural Brain Research, 58: 155-165.
41. Hogg S (1996). A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacology, Biochemistry and Behavior, 54: 21-30.
42. Montgomery KC (1955). The relation between fear induced by novel stimulation and exploratory behavior. Journal of Comparative and Physiological Psychology, 48: 254-260.
43. Handley SL & Mithani S (1984). Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedeberg's Archives of Pharmacology, 327: 1-5.
44. Pellow S. Chopin P, File SE & Briley M (1985). Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods, 14: 149-167.
45. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology, 92: 180-185.
46. Rex A, Fink H & Marsden CA (1994). Effects of BOC-CCK-4 and L 365,260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus-maze. Neuropharmacology, 33: 559-565.
47. Hendrie CA, Eilam D & Weiss SM (1994). Effects of diazepam and buspirone in two models of anxiety in wild voles (Microtus socialis). Journal of Psychopharmacology, Abstract Book, A46, 181.
48. Yannielli PC, Kanterewicz BI & Cardinali DP (1996). Daily rhythms in spontaneous and diazepam-induced anxiolysis in Syrian hamsters. Pharmacology, Biochemistry and Behavior, 54: 651-656.
49. Handley SL & McBlane JW (1993). Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors. Behavioural Brain Research, 58: 203-210.
50. Moser PC (1989). An evaluation of the plus-maze test using the novel anxiolytic buspirone. Psychopharmacology, 99: 48-53.
51. Dawson GR & Tricklebank MD (1995). Use of the elevated plus-maze in the search for novel anxiolytic agents. Trends in Pharmacological Sciences, 16: 33-36.
52. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology. Wiley, Chichester, 107-132.
53. Rodgers RJ (1991). A step in the right direction. Journal of Psychopharmacology, 5: 316-319.
54. Falter U, Gower AJ & Gobert J (1992). Resistance of baseline activity in the elevated plus-maze to exogenous influences. Behavioural Pharmacology, 3: 123-128.
55. Shepherd JK (1992). Preliminary evaluation of an elevated 'zero-maze' as a model of anxiety in laboratory rats. Journal of Psychopharmacology, 6: A56, 223.
56. Adamec RE & Shallow T (1993). Lasting effects on rodent anxiety of a single exposure to a cat. Physiology and Behavior, 54: 101-109.
57. Lorenz K (1973). The fashionable fallacy of dispensing with description. Naturwissenschaften, 60: 1-9.
58. Tinbergen N (1963). On the aims and methods of ethology. Zeitschrift für Tierpsychologie, 20. 410-433.
59. Thorpe WH (1979). The Origins and Rise of Ethology. Heinemann, London.
60. Lee C & Rodgers RJ (1990). Antinociceptive effects of plus-maze exposure: influence of opiate receptor manipulations. Psychopharmacology, 102: 507-513.
61. Rodgers RJ, Cole JC, Cobain MR, Daly P, Doran PJ, Eells JR & Wallis P (1992). Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP. Behavioural Pharmacology, 3: 621-634.
62. Treit D, Menard J & Royan C (1993). Anxiogenic stimuli in the elevated plus-maze. Pharmacology, Biochemistry and Behavior, 44: 463-469.
63. Rodgers RJ & Johnson NJT ( 1995). Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze. Pharmacology, Biochemistry and Behavior, 52: 297-303.
64. Cruz APM, Frei F & Graeff FG (1994). Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacology, Biochemistry and Behavior, 49: 171-176.
65. Fernandes C & File SE (1996). The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacology, Biochemistry and Behavior, 54: 31-40.
66. McCreary AC, McBlane JW, Spooner HA & Handley SL (1996). 5-HT system and anxiety: multiple mechanisms in the elevated plus-maze. Polish Journal of Pharmacology, 48: 1-12.
67. Trullas R & Skolnick P (1993). Differences in fear-motivated behaviors among inbred mouse strains. Psychopharmacology, 111: 323-331.
68. Rodgers RJ & Cole JC (1993). Influence of social isolation, gender, strain and prior novelty on plus-maze behaviour in mice. Physiology and Behavior, 54: 729-736.
69. Holmes A & Rodgers RJ (1996). Factor analysis of behavioural responses to repeated testing in the plus-maze Journal of Psychopharmacology, 10 (Suppl): A47, 185.
70. Blanchard RJ, Brain PF, Parmigiani S & Blanchard DC (1989). Ethoexperimental Approaches to the Study of Behavior, Kluwer, Dordrecht.
71. Rodgers RJ & Randall JI (1986). Acute non-opioid analgesia in defeated male mice. Physiology and Behavior, 36: 947-950.
72. Rodgers RJ & Randall JI (1986). Resident's scent: a critical factor in acute analgesic reaction to defeat experience in male mice. Physiology and Behavior, 37: 317-322.
73. Rodgers RJ & Randall JI (1987). Benzodiazepine ligands, nociception and defeat analgesia in male mice. Psychopharmacology, 91: 304-315.
74. Rodgers RJ & Randall JI (1988). Blockade of non-opioid analgesia in male mice by selective neuronal and non-neuronal benzodiazepine recognition site ligands. Psychopharmacology, 96: 45-54.
75. 1A anxiolytics, buspirone, gepirone and ipsapirone. Psychopharmacology, 99: 374-380.
76. 3 receptor antagonists, ICS 205-930, MDL 72222, MDL 73147 and MDL 72699. Neuropharmacology, 31: 553-560.
77. Rodgers RJ (1995). Neuropharmacological aspects of adaptive pain inhibition in murine 'victims' of aggression. Aggressive Behavior, 21: 29-39.
78. Rodgers RJ & Cole JC (1993). Anxiety enhancement in the elevated plus-maze by immediate prior exposure to social Stressors. Physiology and Behavior, 53: 383-388.
79. Cole JC & Rodgers RJ (1993). An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro16-6028) in the murine elevated plus-maze. Behavioural Pharmacology, 4: 573-580.
80. B) receptor ligands in the elevated plus-maze test of anxiety in mice. Psychopharmacology, 124: 355-364.
81. Cole JC & Rodgers RJ (1995). Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze. Pharmacology, Biochemistry and Behavior, 52: 473-478.
82. Rodgers RJ, Cutler MG & Jackson JE (1996). Behavioural effects of subchronic chlordiazepoxide, maprotiline and fluvoxamine, II, The elevated plus-maze. Pharmacology, Biochemistry and Behavior (in press).
83. Shepherd JK, Grewal SS, Fletcher A, Bill DJ & Dourish CT (1994). Behavioural and pharmacological characterization of the elevated zero-maze as an animal model of anxiety. Psychopharmacology, 116: 56-64.
84. Griebel G, Sanger DJ & Perrault G (1996). The use of the rat elevated plus-maze to discriminate non-selective and BZ-1(ω1)-selective benzodiazepine receptor ligands, Psychopharmacology, 124: 245-254.
85. Rodgers RJ, Cole JC, Aboualfa K & Stephenson LH (1995). Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze. Pharmacology, Biochemistry and Behavior, 52: 805-813.
86. Dalvi A & Rodgers RJ (1996). GABAergic influences on plus-maze behaviour in mice. Psychopharmacology, 128: 380-397.
87. Rodgers RJ & Dalvi A (1997). Anxiety, defence and the elevated plus-maze. Neuroscience and Biobehavioral Reviews (in press).
88. A receptor function. Trends in Pharmacological Sciences, 16: 295-303.
89. Rodgers RJ & Johnson NJT (1996). Neuroactive steroid influences on anxiety. Behavioural Pharmacology, 7 (Suppl 1): 96 (Abstract).
90. Johnson NJT & Rodgers RJ (1996). Modulation of anxiety-related behaviour in mice by 5ß-dihydroprogesterone (5ß-DHP). Journal of Psychopharmacology, 10 (Suppl): A24, 93.
91. Olivier B, Mos J, van Oorschot R & Hen R (1995). Serotonin receptors and animal models of aggressive behavior. Pharmacopsychiatry, 28 (Suppl): 80-90.
92. Kemble ED, Thornton AE & Schultz LA (1987). Some fear-potentiating effects of fluprazine hydrochloride in mice. Aggressive Behavior, 13: 269-280.
93. Cole JC & Rodgers RJ (1994). Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol. Psychopharmacology. 114: 288-296.
94. Griebel G, Rodgers RJ, Perrault G & Sanger DJ (1996). Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacology, Biochemistry and Behavior (in press).
95. 1A receptor agonist, flesinoxan. Pharmacology, Biochemistry and Behavior, 48: 959-963.
96. Cao B-J & Rodgers RJ (1997) Different behavioural profiles of the R(+)- and S(-)-enantiomers of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the murine elevated plus-maze. Behavioural Pharmacology (in press).
97. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology, 121: 1-26.
98. 1A receptor antagonists: utility as research tools and therapeutic agents Trends in Pharmacological Sciences, 14: 441-448.
99. 1A receptor antagonist, in the murine elevated plus-maze test. European Journal of Pharmacology, 261: 321-325.
100. 1A receptor antagonist, in the murine elevated plus-maze. Psychopharmacology (in press).
101. 1 A. Pharmacology, Biochemistry and Behavior (in press).
102. 1Areceptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190. Pharmacology, Biochemistry and Behavior (in press).
103. 1A receptor ligands in dorsal raphe and ventral hippocampus. Pharmacology, Biochemistry and Behavior, 54: 123-128.
104. 1A receptors in the median raphe nucleus and dorsal hippocampus may mediate anxiolytic and anxiogenic behaviours, respectively, European Journal of Pharmacology, 264: 259-264.
105. Hodges H. Green S & Glenn B (1987). Evidence that the amygdala is involved in benzodiazepine and serotonergic effects on punished responding but not discrimination. Psychopharmacology, 92: 491-504.
106. Bill DJ, Knight M, Forster EA & Fletcher A (1991). Direct evidence for an important species difference in the mechanism of 8-OH-DPAT-induced hypothermia. British Journal of Pharmacology, 103: 1857-1864.
107. Klein DF (1981). Anxiety reconceptualized. In: Klein DF & Rabkin J (Editors), Anxiety: New Research and Changing Concepts. Raven Press, New York, 235-262.
108. Nutt DJ (1990). The pharmacology of human anxiety. Pharmacology and Therapeutics, 47: 233-266.
109. Ballenger JC (1990). The Neurobiology of Panic. Wiley-Liss, New York.
110. Den Boer JA, Westenberg HGM, De Leeuw AS & van Vliet IM (1995). Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine. International Clinical Psychopharmacology, 9 (Suppl 4): 47-52.
111. Rodgers RJ, Cutler MG & Jackson JE (1996). Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine, II. The elevated plus-maze Pharmacology, Biochemistry and Behavior (in press).
112. File SE & Zangrossi H (1991). 'One-trial tolerance' to the anxiolytic actions of benzodiazepines in the elevated plus-maze, or the development of a phobic state? Psychopharmacology, 110: 240-244.
113. Rodgers RJ, Johnson NJT, Norton SJ & Cole JC (1995). Effects of ritanserin and 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) in the murine elevated plus-maze test of anxiety: an ethopharmacological study. Journal of Psychopharmacology, 9: 38-42.
114. 3 receptor antagonists, ondansetron and WAY 100289 in the elevated plus-maze test of anxiety in mice. Psychopharmacology, 117: 306-312.
115. Rodgers RJ & Cole JC (1995). The effects of scopolamine and its quaternary analogue in the murine elevated plus-maze test of anxiety. Behavioural Pharmacology, 6: 283-289.
116. Rodgers RJ, Nikulina EM & Cole JC (1994). Dopamine D1 and D2 receptor ligands modulate the behaviour of mice in the elevated plus-maze. Pharmacology, Biochemistry and Behavior, 49: 985-995.
117. Cole JC, Burroughs GJ, Laverty CR, Sheriff NC, Sparham EA & Rodgers RJ (1995). Anxiolytic-like effects of yohimbine in the murine plus-maze: strain independence and evidence against α2-adrenoceptor mediation. Psychopharmacology, 118: 425-436.
118. 3 receptor agonist, 7-OH-DPAT. Pharmacology, Biochemistry and Behavior, 54: 79-84.
119. Costall B, Hendrie CA, Kelly ME & Naylor RJ (1987). Actions of sulpiride and tiapride in a simple model of anxiety in mice. Neuropharmacology, 26: 195-200.
120. Dourish CT, Grewal SS, Shepherd JK, Stanhope KJ, Bill DJ & Fletcher A (1995). Benefits of ethological analysis of behaviour. Trends in Pharmacological Sciences, 16: 260.